Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 3/2018

04.01.2018 | Original Article – Clinical Oncology

Risk factors for unplanned discontinuation of scheduled treatment in elderly patients with castration-resistant prostate cancer: results of the IBuTu study

verfasst von: Friedemann Honecker, Ulrich Wedding, Gerd Kallischnigg, Axel Schroeder, Jörg Klier, Thomas Frangenheim, Lothar Weißbach

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To gain knowledge about the factors associated with discontinuation of scheduled treatment in elderly men with castration-resistant prostate cancer (CRPC).

Methods

Patients ≥ 70 years with CRPC starting a new line of treatment were included in a prospective cohort study. A geriatric assessment (CGA) was performed at baseline, including comorbidity, mobility, functional/mental/nutritional status, as well as depression. Furthermore, pain intensity, quality of life, ECOG-performance status, and physicians’ and patients’ perception of health were documented. Reasons for and factors associated with discontinuation of scheduled treatment were analysed by univariate and multivariate analysis.

Results

After inclusion of 177 of 300 planned patients, the study was closed due to slow recruitment. 160 patients were eligible for final analysis. Median age was 77.5 years. 46% received chemotherapy, and 54% hormonal treatment. Discontinuation of scheduled treatment occurred in 91 patients (57.6%). The main reasons were progressive disease/death in 63%, adverse events/toxicity in 22%, and withdrawal of consent in 8%. In bivariate analyses, factors associated with discontinuation of treatment were age ≥ 80 years, ECOG PS ≥ 2, compromised/poor health status (physicians’/patients’ assessment), and compromised functional or nutritional status. In multivariate analysis, the only remaining factor independently associated with discontinuation of scheduled treatment was impairment of activities of daily living (ADL < 100 points) (OR = 4.2 for discontinuation; p < 0.05).

Conclusion

Despite limitations due to early termination of the study, our results demonstrate that discontinuation of scheduled treatment was common, and that compromised ADL seems to be a significant risk factor for treatment failure in elderly patients with CRPC.
Literatur
Zurück zum Zitat Balducci L, Extermann M (2000) Management of cancer in the older person: a practical approach. Oncologist 5(3):224–37CrossRefPubMed Balducci L, Extermann M (2000) Management of cancer in the older person: a practical approach. Oncologist 5(3):224–37CrossRefPubMed
Zurück zum Zitat Bellera CA et al (2012) Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol 23(8):2166–2172CrossRefPubMed Bellera CA et al (2012) Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol 23(8):2166–2172CrossRefPubMed
Zurück zum Zitat Decoster L et al (2015) Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations. Ann Oncol 26(2):288–300CrossRefPubMed Decoster L et al (2015) Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations. Ann Oncol 26(2):288–300CrossRefPubMed
Zurück zum Zitat Droz JP et al (2014) Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncol 15(9):e404–e414CrossRefPubMed Droz JP et al (2014) Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncol 15(9):e404–e414CrossRefPubMed
Zurück zum Zitat Extermann M, Boler I, Reich R et al (2012) Predicting the risk of chemotherapy toxicity in older patients: the chemotherapy risk assessment scale for high-age patients (CRASH) score. Cancer 1:3377–3386CrossRef Extermann M, Boler I, Reich R et al (2012) Predicting the risk of chemotherapy toxicity in older patients: the chemotherapy risk assessment scale for high-age patients (CRASH) score. Cancer 1:3377–3386CrossRef
Zurück zum Zitat Hutchins LF et al (1999) Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341(27):2061–2067CrossRefPubMed Hutchins LF et al (1999) Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341(27):2061–2067CrossRefPubMed
Zurück zum Zitat Pallis AG et al (2010) EORTC elderly task force position paper: approach to the older cancer patient. Eur J Cancer 46(9):1502–1513CrossRefPubMed Pallis AG et al (2010) EORTC elderly task force position paper: approach to the older cancer patient. Eur J Cancer 46(9):1502–1513CrossRefPubMed
Zurück zum Zitat Wildiers H, Mauer M, Pallis A et al (2013) End points and trial design in geriatric oncology research: a Joint european organisation for research and treatment of cancer—alliance for clinical trials in Oncology—International Society of Geriatric Oncology Position Article. J Clin Oncol 31(29):3711–3718CrossRefPubMed Wildiers H, Mauer M, Pallis A et al (2013) End points and trial design in geriatric oncology research: a Joint european organisation for research and treatment of cancer—alliance for clinical trials in Oncology—International Society of Geriatric Oncology Position Article. J Clin Oncol 31(29):3711–3718CrossRefPubMed
Metadaten
Titel
Risk factors for unplanned discontinuation of scheduled treatment in elderly patients with castration-resistant prostate cancer: results of the IBuTu study
verfasst von
Friedemann Honecker
Ulrich Wedding
Gerd Kallischnigg
Axel Schroeder
Jörg Klier
Thomas Frangenheim
Lothar Weißbach
Publikationsdatum
04.01.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 3/2018
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-017-2577-1

Weitere Artikel der Ausgabe 3/2018

Journal of Cancer Research and Clinical Oncology 3/2018 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.